Companies Dominating the Vaso Occlusive Crisis Landscape
- Novartis Pharmaceuticals Corporation
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bristol-Myers Squibb
- Pfizer Inc.
- Global Blood Therapeutics
- AstraZeneca
- Sanofi
- GlaxoSmithKline
- Regeneron Pharmaceuticals
- Bluebird Bio
- Emmaus Life Sciences, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of vaso occlusive crisis is assessed at USD 11.56 billion.
The vaso occlusive crisis market size was over USD 10.82 billion in 2024 and is projected to reach USD 29.78 billion by 2037, growing at around 8.1% CAGR during the forecast period i.e., between 2025-2037. Increasing demand for the pharmaceutical sector will fuel the market growth.
Asia Pacific industry is set to dominate majority revenue share of 38% by 2037, impelled by accelerating advancements in SCD in the region.
The major players in the market are Novartis Pharmaceuticals Corporation, Bristol-Myers Squibb, Pfizer Inc., Global Blood Therapeutics, AstraZeneca, Sanofi, and others.
